Tag: antibody-drug conjugates
January 18, 2019
Immunomedics Receives Complete Response Letter From FDA for Sacituzumab Govitecan Biologics License Application
Immunomedics (NASDAQ:IMMU) a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced it has received a Complete Response Letter... December 6, 2018
Immunomedics Provides Clinical Updates on Breast Cancer Programs With Sacituzumab Govitecan
Immunomedics (NASDAQ:IMMU) a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today presents updated Phase 2 results at the 2018... August 24, 2018
Immunomedics Announces Fourth Quarter and Fiscal Year 2018 Results and Provides Corporate Update
Immunomedics (NASDAQ:IMMU) a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), reported financial results for the fourth quarter and... June 13, 2018
Immunomedics Announces Pricing of Public Offering of Common Stock
Immunomedics (NASDAQ:IMMU) a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), announced the pricing of an underwritten public offering... June 6, 2018
